Company Overview and News
(Bloomberg) -- The failure of a $27 billion project last week may offer a lesson to natural gas exporters: Go small or go home.
NEW YORK (Bloomberg) -- The failure of a $27-billion project last week may offer a lesson to natural gas exporters: Go small or go home.
Shares of Chinese coal-fired power generators surged as much as 6 to 8 per cent on expectations of a wholesale power price increase next month, which is likely to bolster profits that have been dented by surging coal costs in the past two years.
Beijing’s plan to launch the long-awaited “green certificate” trading scheme is part of an effort to ease the snowballing deficit of the state-run renewable energy subsidy fund, and shift part of the financial burden for reducing pollution from consumers to coal-fired power producers.
Shares of mainland Chinese coal-fired power producers listed in Hong Kong ended flat or fell slightly on Thursday after Beijing decided not to lift the prices they charge for their electricity despite higher coal prices.
Companies in Shandong have been ordered to either cut output or shut down— Reuters picBEIJING, Dec 20 — A major city in China’s Shandong province has ordered seven big coal-fired power plants to cut output by nearly two-thirds as part of a clampdown on pollution as smog blanketed northern parts of the country.
Highly debt leveraged Chinese companies in the utilities and airlines industries are among the most exposed to the risk of higher borrowing costs if the recent rise in interbank rates becomes a sustained trend, according to analysts.
Weak power demand and rapid growth in new generation capacity to hurt profits of key players
The mainland’s power producers are facing a grimmer profit outlook in the next few years, due to tepid power demand growth and sharp falls in plant utilisation amid fast-growing generating capacity and industry reform aimed at raising price competition.
2018-05-25 - Asif
Overview Heron is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments that address some of the most important unmet patient needs. Heron Therapeutics is developing novel, patient-focused solutions that apply its innovative science and technologies to already approved pharmacological agents for patients suffering from cancer or pain. On August 9, 2016, its first commercial product, SUSTOL, was approved by the FDA. The company developed SUSTOL for the prevention of chemotherapy-induced nausea and vomiting (“CINV”). SUSTOL is indicated, in combination with other antiemetics, in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (“MEC”) or anthracycline and cyclophosphamide (“AC”) combination chemotherapy regimens. The company commenced commercial sales of SUSTOL in the U.S. in October 2016. On November 9, 2017...
2018-05-25 - Asif
Overview The company's mission is to deliver high-speed coherent optical interconnect products that transform communications networks, relied upon by cloud infrastructure operators and content and communication service providers, through improvements in performance and capacity and reductions in associated costs. By converting optical interconnect technology to a silicon-based technology, a process the company refer to as the siliconization of optical interconnect, the company believe Acacia Communications is leading a disruption that is analogous to the computing industry’s integration of multiple functions into a microprocessor. The company's products include a family of low-power coherent digital signal processor application-specific integrated circuits, or DSP ASICs, and silicon photonic integrated circuits, or silicon PICs, which Acacia Communications has integrated into families of optical interconnect modules with transmission speeds ranging from 100 to 400 gigabits per ...
2018-05-21 - Asif
Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...